Noninvasive new Cat B and PKa methods to detect liver fibrosis may be clinically helpful in assessing the stage of fibrosis in patients with no clear indication for a liver biopsy, such as patients with chronic hepatitis B (CHB) and persistently normal serum alanine aminotransferase (ALT), patients with CHC or CHB who require follow-up assessment of the stage of fibrosis during or after treatment [45,46], and autoimmune hepatitis patients who require assessment after prolonged immunosuppressive therapy [47]. This evidence concerns the gene GPT and autoimmune hepatitis.